Difloxacin hydrochloride

Synonyms: 盐酸二氟沙星; A-56619 hydrochloride
Difloxacin hydrochloride (A-56619 hydrochloride) 是一种具有口服活性的杀菌剂,通过抑制细菌 DNA gyrase 发挥浓度依赖性杀菌作用,在体外对多种革兰氏阳性菌和革兰氏阴性菌具有很强的活性,可用于大肠杆菌病和金黄色葡萄球菌感染的相关研究。
产品编号: MS-X16772 纯度: 99.52% CAS No.: 91296-86-5 分子式: C21H20ClF2N3O3 分子量: 435.85
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

Difloxacin hydrochloride (A-56619 hydrochloride) 是一种具有口服活性的杀菌剂,通过抑制细菌 DNA gyrase 发挥浓度依赖性杀菌作用,在体外对多种革兰氏阳性菌和革兰氏阴性菌具有很强的活性,可用于大肠杆菌病和金黄色葡萄球菌感染的相关研究。

生物实验数据

生物活性 Difloxacin hydrochloride (A-56619 hydrochloride) is an orally active bactericidal agent that inhibits bacterial DNA gyrase, exhibits concentration-dependent bactericidal activity, shows potent in vitro activity against a variety of Gram-positive and Gram-negative bacteria, and can be used in research related to colibacillosis and Staphylococcus aureus infection.
体外研究
(In Vitro)

Difloxacin (24-48 h) hydrochloride 可在体外抑制并清除 E. coli O78 野外菌株,其 MIC 为 0.02 µg/mL,MBC 为 0.04 µg/mL。
Difloxacin (0.04-12.5 µg/mL) hydrochloride 在正常鸡血清中体外表现出 3.99% 的蛋白结合率。
Difloxacin hydrochloride 具有广谱的体外抗菌活性,针对革兰氏阳性菌 (Staphylococcus aureus、Streptococcus pyogenes、Streptococcus pneumoniae、Streptococcus faecalis) 和革兰氏阴性菌 (Escherichia coli、Klebsiella pneumoniae、Salmonella typhimurium、Proteus mirabilis、Proteus vulgaris、Serratia marcescens、Providencia stuartii、Pseudomonas aeruginosa) 的分离株。
Difloxacin (1-25 μg/mL; 72 h) hydrochloride 可呈剂量依赖性且可逆地抑制刀豆蛋白 A (ConA) 诱导的人外周血单个核细胞增殖;25 μg/mL 浓度下细胞存活率为 92%。

体内研究
(In Vivo)

Difloxacin (10 mg/kg;静脉注射、口服;单剂量) hydrochloride 在健康肉鸡体内的血清浓度可持续维持在 E. coli MIC 以上,口服生物利用度高达 86.2%,静脉注射消除半衰期为 3.7 h。
Difloxacin (皮下注射、口服;每日 2 次;感染后 1 h 和 5 h) hydrochloride 在 CF-1 小鼠中对致死性金黄色葡萄球菌 10649 感染表现出的 ED50 为:皮下给药每日 1.7 mg/kg,口服给药每日 3.2 mg/kg。

Animal Model: CF-1 (female, 20 g)
Dosage: 1.7 mg/kg per day (subcutaneous); 3.2 mg/kg per day (oral)
Administration: subcutaneous; twice daily; post-infection at 1 and 5 h; oral; twice daily; post-infection at 1 and 5 h
Result: Achieved an ED50 of 1.7 mg/kg per day via subcutaneous administration.
Achieved an ED50 of 3.2 mg/kg per day via oral administration.
Animal Model: CF-1 (female, 20 g)
Dosage: 5.2 mg/kg per day (subcutaneous); 8.7 mg/kg per day (oral)
Administration: subcutaneous; twice daily; post-infection at 1 and 5 h; oral; twice daily; post-infection at 1 and 5 h
Result: Achieved an ED50 of 5.2 mg/kg per day via subcutaneous administration.
Achieved an ED50 of 8.7 mg/kg per day via oral administration.
Animal Model: CF-1 (female, 20 g)
Dosage: 14.9 mg/kg per day (subcutaneous); 19.6 mg/kg per day (oral)
Administration: subcutaneous; twice daily; post-infection at 1 and 5 h; oral; twice daily; post-infection at 1 and 5 h
Result: Achieved an ED50 of 14.9 mg/kg per day via subcutaneous administration.
Achieved an ED50 of 19.6 mg/kg per day via oral administration.
Animal Model: CF-1 (female, 20 g)
Dosage: 2.2 mg/kg per day (subcutaneous); 3.9 mg/kg per day (oral)
Administration: subcutaneous; twice daily; post-infection at 1 and 5 h; oral; twice daily; post-infection at 1 and 5 h
Result: Achieved an ED50 of 2.2 mg/kg per day via subcutaneous administration.
Achieved an ED50 of 3.9 mg/kg per day via oral administration.
Animal Model: CF-1 (female, 20 g)
Dosage: 0.5 mg/kg per day (subcutaneous); 1.1 mg/kg per day (oral)
Administration: subcutaneous; twice daily; post-infection at 1 and 5 h; oral; twice daily; post-infection at 1 and 5 h
Result: Achieved an ED50 of 0.5 mg/kg per day via subcutaneous administration.
Achieved an ED50 of 1.1 mg/kg per day via oral administration.
Animal Model: CF-1 (female, 20 g)
Dosage: 1.6 mg/kg per day (subcutaneous); 1.4 mg/kg per day (oral)
Administration: subcutaneous; twice daily; post-infection at 24 and 28 h; oral; twice daily; post-infection at 24 and 28 h
Result: Achieved an ED50 of 1.6 mg/kg per day via subcutaneous administration.
Achieved an ED50 of 1.4 mg/kg per day via oral administration.
Animal Model: CF-1 (female, 20 g)
Dosage: 2.9 mg/kg per day (subcutaneous); 7.3 mg/kg per day (oral)
Administration: subcutaneous; twice daily; post-infection at 1 and 5 h; oral; twice daily; post-infection at 1 and 5 h
Result: Achieved an ED50 of 2.9 mg/kg per day via subcutaneous administration.
Achieved an ED50 of 7.3 mg/kg per day via oral administration.
Animal Model: CF-1 (female, 20 g)
Dosage: 4.2 mg/kg per day (subcutaneous); 14.9 mg/kg per day (oral)
Administration: subcutaneous; twice daily; post-infection at 1 and 5 h; oral; twice daily; post-infection at 1 and 5 h
Result: Achieved an ED50 of 4.2 mg/kg per day via subcutaneous administration.
Achieved an ED50 of 14.9 mg/kg per day via oral administration.
Animal Model: CF-1 (female, 20 g)
Dosage: 1.5 mg/kg per day (subcutaneous); 1.9 mg/kg per day (oral)
Administration: subcutaneous; twice daily; post-infection at 1 and 5 h; oral; twice daily; post-infection at 1 and 5 h
Result: Achieved an ED50 of 1.5 mg/kg per day via subcutaneous administration.
Achieved an ED50 of 1.9 mg/kg per day via oral administration.
Animal Model: CF-1 (female, 20 g)
Dosage: 3.7 mg/kg per day (subcutaneous); 4.9 mg/kg per day (oral)
Administration: subcutaneous; twice daily; post-infection at 1 and 5 h; oral; twice daily; post-infection at 1 and 5 h
Result: Achieved an ED50 of 3.7 mg/kg per day via subcutaneous administration.
Achieved an ED50 of 4.9 mg/kg per day via oral administration.
Animal Model: CF-1 (female, 20 g)
Dosage: 5.2 mg/kg per day (subcutaneous)
Administration: subcutaneous; twice daily; post-infection at 1 and 5 h
Result: Achieved an ED50 of 5.2 mg/kg per day via subcutaneous administration.
性状 固体
颜色 White to off-white

化学信息

分子量 435.85
分子式 C21H20ClF2N3O3
CAS No. 91296-86-5
别名 盐酸二氟沙星; A-56619 hydrochloride

储存&溶解度

储存方式

4°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

H2O 中的溶解度 : 5 mg/mL (11.47 mM; 超声助溶 (<60°C))

可选溶剂浓度1 mg5 mg10 mg25 mg
H2O1 mM2.2944 mL11.4718 mL22.9437 mL57.3592 mL
5 mM0.4589 mL2.2944 mL4.5887 mL11.4718 mL
10 mM0.2294 mL1.1472 mL2.2944 mL5.7359 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础